Shah Saumil R, Hochberg Claudia P, Pinto Duane S, Gibson C Michael
Division of Cardiology, Beth Israel Deaconess Medical Center, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA.
Curr Cardiol Rep. 2007 Jul;9(4):281-8. doi: 10.1007/BF02938376.
Management of ST-elevation myocardial infarction requires rapid, sustained and early restoration of flow in the infarct-related artery to minimize myocardial damage and to improve clinical outcomes. Primary percutaneous coronary intervention (PCI) is the preferred therapy but is limited by restricted availability and delays in implementation. Fibrinolytic administration is widely available but is limited by its failure to achieve Thrombolysis in Myocardial Infarction grade 3 flow in many patients, re-infarction, and intracranial hemorrhage. A combination approach to reperfusion--facilitated PCI--involves the administration of a pharmacologic agent to improve reperfusion with PCI. The evidence supporting facilitated PCI varies according to the pharmacologic regimen at this time.
ST段抬高型心肌梗死的治疗需要迅速、持续且尽早恢复梗死相关动脉的血流,以尽量减少心肌损伤并改善临床结局。直接经皮冠状动脉介入治疗(PCI)是首选治疗方法,但受限于可及性受限和实施延迟。纤维蛋白溶解剂的应用广泛,但在许多患者中存在无法达到心肌梗死溶栓3级血流、再梗死和颅内出血等局限性。一种联合再灌注方法——易化PCI——涉及使用一种药物制剂以改善PCI的再灌注效果。目前,支持易化PCI的证据因药物治疗方案而异。